| Jaemi Keith, MD | |
|
6064 S Fort Apache Rd Ste 100, Las Vegas, NV 89148-5350 | |
| (702) 940-8007 | |
| (702) 832-1940 |
| Full Name | Jaemi Keith |
|---|---|
| Gender | Female |
| Speciality | Interventional Pain Management |
| Experience | 20 Years |
| Location | 6064 S Fort Apache Rd Ste 100, Las Vegas, Nevada |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215145792 | NPI | - | NPPES |
| 1215145792 | Medicaid | NV |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Andrew Hall Md Pllc | 8628308962 | 4 |
News Archive
Researchers at the University of Colorado Anschutz Medical Campus are studying the detection of prenatal marijuana use in a legalized environment. The study of marijuana use in pregnancy is only possible in a few states.
A research group discovered a new function of the chromosomal terminus, which may lead to the clarification of the mechanism for developing abnormal telomere structure such as multiple malformation and mental retardation.
A new Welsh-developed drug to help alleviate the suffering of shingles could move a step closer for patients if the final stage of testing is given the go-ahead.
The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.
› Verified 1 days ago
| Entity Name | Andrew Hall Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588121941 PECOS PAC ID: 8628308962 Enrollment ID: O20190930000279 |
News Archive
Researchers at the University of Colorado Anschutz Medical Campus are studying the detection of prenatal marijuana use in a legalized environment. The study of marijuana use in pregnancy is only possible in a few states.
A research group discovered a new function of the chromosomal terminus, which may lead to the clarification of the mechanism for developing abnormal telomere structure such as multiple malformation and mental retardation.
A new Welsh-developed drug to help alleviate the suffering of shingles could move a step closer for patients if the final stage of testing is given the go-ahead.
The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jaemi Keith, MD 6064 S Fort Apache Rd Ste 100, Las Vegas, NV 89148-5350 Ph: (702) 940-8007 | Jaemi Keith, MD 6064 S Fort Apache Rd Ste 100, Las Vegas, NV 89148-5350 Ph: (702) 940-8007 |
News Archive
Researchers at the University of Colorado Anschutz Medical Campus are studying the detection of prenatal marijuana use in a legalized environment. The study of marijuana use in pregnancy is only possible in a few states.
A research group discovered a new function of the chromosomal terminus, which may lead to the clarification of the mechanism for developing abnormal telomere structure such as multiple malformation and mental retardation.
A new Welsh-developed drug to help alleviate the suffering of shingles could move a step closer for patients if the final stage of testing is given the go-ahead.
The University of Colorado Cancer Center and Loxo Oncology, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of targeted cancer therapies, today announced the publication of a research brief in the online edition of the journal Cancer Discovery, describing the first patient with a tropomyosin receptor kinase (TRK) fusion cancer enrolled in the Phase 1 dose escalation trial of LOXO-101, the only selective TRK inhibitor in clinical development.
› Verified 1 days ago
Mark Livingston, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 9127 W Russell Rd Ste 110, Las Vegas, NV 89148 Phone: 702-878-0070 Fax: 702-209-2064 | |
Dr. Charles Minh, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 205 Elder View Dr, Las Vegas, NV 89138 Phone: 702-907-6464 | |
Ryan Nimer, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7160 Rafael Rivera Way Ste 210, Las Vegas, NV 89113 Phone: 702-878-0070 Fax: 702-209-2064 | |
Liam Kelly Sullivan, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 7160 Rafael Rivera Way Ste 210, Las Vegas, NV 89113 Phone: 702-878-0070 Fax: 702-805-0307 | |
James Murphy, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2635 Box Canyon Dr, Las Vegas, NV 89128 Phone: 702-386-4700 Fax: 702-386-4701 | |
Scott Young, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7250 Peak Dr Ste 100, Las Vegas, NV 89128 Phone: 702-386-4700 Fax: 702-386-4701 | |
Dr. Derek Michael Goffstein, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 7160 Rafael Rivera Way Ste 210, Las Vegas, NV 89113 Phone: 702-878-0070 Fax: 702-805-0307 |